|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
|
GT200500281A
(es)
*
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0500785D0
(en)
*
|
2005-01-14 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
HRP20120786T1
(hr)
*
|
2006-02-02 |
2012-11-30 |
Millennium Pharmaceuticals, Inc. |
Inhibitori aktivirajuä†eg enzima e1
|
|
US20090220515A1
(en)
*
|
2006-02-13 |
2009-09-03 |
Mount Sinai School Of Medicine |
Treatment and prevention of renal disease
|
|
GB0607953D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607948D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607944D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
GB0607950D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
HRP20120494T1
(hr)
|
2006-04-21 |
2012-08-31 |
Novartis Ag |
Derivati purina za uporabu kao agonista adenozin a2a receptora
|
|
GB0607945D0
(en)
*
|
2006-04-21 |
2006-05-31 |
Novartis Ag |
Organic compounds
|
|
EP1889846A1
(en)
|
2006-07-13 |
2008-02-20 |
Novartis AG |
Purine derivatives as A2a agonists
|
|
US8008307B2
(en)
|
2006-08-08 |
2011-08-30 |
Millennium Pharmaceuticals, Inc. |
Heteroaryl compounds useful as inhibitors of E1 activating enzymes
|
|
ME02789B
(me)
|
2006-08-08 |
2011-06-30 |
Millennium Pharm Inc |
Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
|
|
EP1903044A1
(en)
*
|
2006-09-14 |
2008-03-26 |
Novartis AG |
Adenosine Derivatives as A2A Receptor Agonists
|
|
CL2007002994A1
(es)
*
|
2006-10-19 |
2008-02-08 |
Wyeth Corp |
Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
|
|
JP2010508835A
(ja)
*
|
2006-11-10 |
2010-03-25 |
ノバルティス アーゲー |
シクロペンテンジオールモノアセテート誘導体
|
|
US7897737B2
(en)
|
2006-12-05 |
2011-03-01 |
Lasergen, Inc. |
3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
|
|
JP2010516254A
(ja)
|
2007-01-18 |
2010-05-20 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ユビキチンに対する新規活性化および転移カスケード
|
|
EP2540727B1
(en)
*
|
2007-08-02 |
2018-07-25 |
Millennium Pharmaceuticals, Inc. |
Sulfamoylating reagent
|
|
AU2013204618B2
(en)
*
|
2007-08-02 |
2015-11-05 |
Takeda Pharmaceutical Company Limited |
Process for the synthesis of E1 activating enzyme inhibitors
|
|
KR20100068286A
(ko)
*
|
2007-10-17 |
2010-06-22 |
노파르티스 아게 |
아데노신 ａ1 수용체 리간드로서의 퓨린 유도체
|
|
US8648085B2
(en)
|
2007-11-30 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
AU2009257369B2
(en)
|
2008-06-11 |
2015-03-26 |
Agilent Technologies, Inc. |
Nucleotides and nucleosides and methods for their use in DNA sequencing
|
|
CN102143965A
(zh)
|
2008-09-08 |
2011-08-03 |
贝林格尔.英格海姆国际有限公司 |
吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
|
|
JP2012503651A
(ja)
*
|
2008-09-26 |
2012-02-09 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
３−デアザネプラノシン誘導体
|
|
UY32531A
(es)
|
2009-03-31 |
2010-10-29 |
Boehringer Ingelheim Int |
Nuevos compuestos para el tratamiento de trastornos del snc
|
|
EP2430026A1
(en)
|
2009-05-14 |
2012-03-21 |
Millennium Pharmaceuticals, Inc. |
Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
|
|
AR077859A1
(es)
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
|
BR112013003097B1
(pt)
|
2010-08-12 |
2021-03-16 |
Boehringer Ingelheim International Gmbh |
6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
|
|
CN103391939B
(zh)
|
2010-12-03 |
2016-03-09 |
Epizyme股份有限公司 |
作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物
|
|
AU2011341441A1
(en)
|
2010-12-03 |
2013-06-20 |
Epizyme, Inc. |
Modulators of histone methyltransferase, and methods of use thereof
|
|
EP2646454B1
(en)
|
2010-12-03 |
2015-07-08 |
Epizyme, Inc. |
7-deazapurine modulators of histone methyltransferase, and methods of use thereof
|
|
US20130040971A1
(en)
|
2011-02-14 |
2013-02-14 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
WO2012158789A2
(en)
|
2011-05-17 |
2012-11-22 |
St. Jude Children's Research Hospital |
Methods and compositions for inhibiting neddylation of proteins
|
|
MY166889A
(en)
|
2011-08-24 |
2018-07-24 |
Millennium Pharm Inc |
Inhibitors of nedd8-activating enzyme
|
|
US20150030601A1
(en)
*
|
2011-10-07 |
2015-01-29 |
Millennium Pharmaceuticals, Inc. |
E1 enzyme mutants and uses thereof
|
|
CA2862580A1
(en)
|
2011-10-28 |
2013-05-02 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to nae inhibitors
|
|
PL2773360T3
(pl)
|
2011-11-03 |
2018-09-28 |
Millennium Pharmaceuticals, Inc. |
Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego
|
|
KR102072041B1
(ko)
|
2011-12-22 |
2020-01-31 |
앨리오스 바이오파마 인크. |
치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
|
|
UA116534C2
(uk)
|
2012-02-17 |
2018-04-10 |
Мілленніум Фармасьютікалз, Інк. |
Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
|
|
US9441007B2
(en)
|
2012-03-21 |
2016-09-13 |
Alios Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
USRE48171E1
(en)
|
2012-03-21 |
2020-08-25 |
Janssen Biopharma, Inc. |
Substituted nucleosides, nucleotides and analogs thereof
|
|
WO2013188881A1
(en)
*
|
2012-06-15 |
2013-12-19 |
President And Fellows Of Harvard College |
Compounds, compositions and methods for treating or preventing neurodegenerative disorders
|
|
CN104684559A
(zh)
*
|
2012-08-03 |
2015-06-03 |
米伦纽姆医药公司 |
针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
|
|
WO2014026198A1
(en)
|
2012-08-10 |
2014-02-13 |
Epizyme, Inc. |
Inhibitors of protein methyltransferase dot1l and methods of use thereof
|
|
EP2892536B1
(en)
|
2012-09-06 |
2019-12-18 |
Epizyme, Inc. |
Method of treating leukemia
|
|
US10662477B2
(en)
|
2012-10-01 |
2020-05-26 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods to predict response to inhibitors and uses thereof
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
AU2014214561C1
(en)
*
|
2013-02-11 |
2019-01-17 |
Mitokinin, Inc. |
Compositions and methods for treating neurodegenerative diseases
|
|
WO2014152566A2
(en)
|
2013-03-15 |
2014-09-25 |
Epizyme, Inc. |
Methods of synthesizing substituted purine compounds
|
|
WO2014145576A2
(en)
|
2013-03-15 |
2014-09-18 |
Northwestern University |
Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
|
|
CN105407973A
(zh)
|
2013-05-14 |
2016-03-16 |
米伦纽姆医药公司 |
Nedd8活化酶抑制剂及化学治疗剂的投与
|
|
KR102307566B1
(ko)
|
2013-06-21 |
2021-10-05 |
제니쓰 에피제네틱스 리미티드 |
신규한 바이사이클릭 브로모도메인 억제제
|
|
CN105473581B
(zh)
|
2013-06-21 |
2019-04-23 |
齐尼思表观遗传学有限公司 |
作为溴结构域抑制剂的新取代的双环化合物
|
|
WO2015002994A2
(en)
|
2013-07-02 |
2015-01-08 |
Millennium Pharmaceuticals, Inc. |
Heteroaryl compounds useful as inhibitors of sumo activating enzyme
|
|
CA2919948C
(en)
|
2013-07-31 |
2020-07-21 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
|
ES2919024T3
(es)
|
2014-02-11 |
2022-07-21 |
Mitokinin Inc |
Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
|
|
CN106661031B
(zh)
*
|
2014-06-24 |
2019-07-23 |
大鹏药品工业株式会社 |
吡咯并嘧啶化合物或其盐、含有其的药物组合物及应用
|
|
BR112016030787B1
(pt)
|
2014-07-01 |
2022-12-20 |
Takeda Pharmaceutical Company Limited |
Entidade química, composição farmacêutica e seu uso
|
|
HK1245246A1
(zh)
|
2014-12-01 |
2018-08-24 |
恒翼生物医药科技(上海)有限公司 |
作为溴域抑制剂的取代吡啶酮
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
CN114702495A
(zh)
|
2015-11-20 |
2022-07-05 |
福马治疗有限公司 |
作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
|
|
TWI623316B
(zh)
*
|
2015-12-22 |
2018-05-11 |
Taiho Pharmaceutical Co Ltd |
Antitumor effect enhancer derived from pyrrolopyrimidine compound
|
|
CN106008394B
(zh)
*
|
2016-05-23 |
2018-12-04 |
中国人民解放军第二军医大学 |
巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
|
|
CN106854208B
(zh)
*
|
2016-11-25 |
2019-04-09 |
成都柏睿泰生物科技有限公司 |
肿瘤抑制剂mln4924的合成方法
|
|
WO2018213258A1
(en)
*
|
2017-05-15 |
2018-11-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of merlin-deficient tumors using nae inhibitors
|
|
WO2018237145A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
JP2020534331A
(ja)
*
|
2017-09-21 |
2020-11-26 |
ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
（（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用
|
|
WO2019109016A1
(en)
|
2017-12-01 |
2019-06-06 |
Millennium Pharmaceuticals, Inc. |
Biomarkers and methods for treatment with nae inhibitors
|
|
CN110218179B
(zh)
*
|
2018-03-02 |
2020-08-04 |
新发药业有限公司 |
一种4-氨基-2-氯-3-硝基吡啶的制备方法
|
|
AU2019301697A1
(en)
|
2018-07-13 |
2021-01-07 |
Il-2Rx, Inc. |
Compounds, compositions, methods, and uses for treating cancer and immunological disorders
|
|
US12435088B2
(en)
|
2018-12-21 |
2025-10-07 |
Memorial Sloan-Kettering Cancer Center |
Salicyl-adenosinemonosulfamate analogs and uses thereof
|
|
JP2022522534A
(ja)
|
2019-04-02 |
2022-04-19 |
アリゴス セラピューティクス インコーポレイテッド |
Ｐｒｍｔ５を標的にする化合物
|
|
CN112079836B
(zh)
*
|
2019-06-13 |
2022-12-13 |
中国科学院上海药物研究所 |
三唑并嘧啶类化合物及其盐、组合物和应用
|
|
EP4319763A4
(en)
*
|
2021-04-09 |
2025-06-11 |
Emory University |
MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES
|
|
WO2025059029A1
(en)
*
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating vexas syndrome
|
|
WO2025073926A1
(en)
*
|
2023-10-05 |
2025-04-10 |
Københavns Universitet |
An inhibitor of sumo e1-enzyme for use in tissue regeneration
|
|
CN117466963A
(zh)
*
|
2023-11-08 |
2024-01-30 |
湖南大学 |
一种羟甲基的保护及脱保护方法
|
|
CN117466965A
(zh)
*
|
2023-11-08 |
2024-01-30 |
湖南大学 |
一种合成碱基序列的方法
|
|
KR20250075265A
(ko)
*
|
2023-11-21 |
2025-05-28 |
한국화학연구원 |
Use1 활성을 억제하는 화합물 유도체, 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
|
|
WO2026015820A1
(en)
*
|
2024-07-12 |
2026-01-15 |
Sobi, Inc. |
Methods of treating vexas
|
|
CN120737113B
(zh)
*
|
2025-09-03 |
2025-11-21 |
湖北师范大学 |
一种三唑并哒嗪类化合物区域选择性c3-h炔基化的方法
|